These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 28436707)

  • 1. SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.
    Herold N; Rudd SG; Sanjiv K; Kutzner J; Bladh J; Paulin CBJ; Helleday T; Henter JI; Schaller T
    Cell Cycle; 2017 Jun; 16(11):1029-1038. PubMed ID: 28436707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
    Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
    Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
    Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
    Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.
    Rassidakis GZ; Herold N; Myrberg IH; Tsesmetzis N; Rudd SG; Henter JI; Schaller T; Ng SB; Chng WJ; Yan B; Ng CH; Ravandi F; Andreeff M; Kantarjian HM; Medeiros LJ; Xagoraris I; Khoury JD
    Blood Cancer J; 2018 Oct; 8(11):98. PubMed ID: 30341277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
    Oellerich T; Schneider C; Thomas D; Knecht KM; Buzovetsky O; Kaderali L; Schliemann C; Bohnenberger H; Angenendt L; Hartmann W; Wardelmann E; Rothenburger T; Mohr S; Scheich S; Comoglio F; Wilke A; Ströbel P; Serve H; Michaelis M; Ferreirós N; Geisslinger G; Xiong Y; Keppler OT; Cinatl J
    Nat Commun; 2019 Aug; 10(1):3475. PubMed ID: 31375673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML.
    Zhang F; Sun J; Tang X; Liang Y; Jiao Q; Yu B; Dai Z; Yuan X; Li J; Yan J; Zhang Z; Fan S; Wang M; Hu H; Zhang C; Lv XB
    Cell Death Dis; 2022 Jul; 13(7):590. PubMed ID: 35803902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.
    Rudd SG; Tsesmetzis N; Sanjiv K; Paulin CB; Sandhow L; Kutzner J; Hed Myrberg I; Bunten SS; Axelsson H; Zhang SM; Rasti A; Mäkelä P; Coggins SA; Tao S; Suman S; Branca RM; Mermelekas G; Wiita E; Lee S; Walfridsson J; Schinazi RF; Kim B; Lehtiö J; Rassidakis GZ; Pokrovskaja Tamm K; Warpman-Berglund U; Heyman M; Grandér D; Lehmann S; Lundbäck T; Qian H; Henter JI; Schaller T; Helleday T; Herold N
    EMBO Mol Med; 2020 Mar; 12(3):e10419. PubMed ID: 31950591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SAMHD1 inhibits epithelial cell transformation in vitro and affects leukemia development in xenograft mice.
    Kodigepalli KM; Li M; Bonifati S; Panfil AR; Green PL; Liu SL; Wu L
    Cell Cycle; 2018; 17(23):2564-2576. PubMed ID: 30474474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells.
    Rothenburger T; Thomas D; Schreiber Y; Wratil PR; Pflantz T; Knecht K; Digianantonio K; Temple J; Schneider C; Baldauf HM; McLaughlin KM; Rothweiler F; Bilen B; Farmand S; Bojkova D; Costa R; Ferreirós N; Geisslinger G; Oellerich T; Xiong Y; Keppler OT; Wass MN; Michaelis M; Cinatl J
    J Exp Clin Cancer Res; 2021 Oct; 40(1):317. PubMed ID: 34641952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis.
    Kodigepalli KM; Bonifati S; Tirumuru N; Wu L
    Cell Cycle; 2018; 17(9):1124-1137. PubMed ID: 29911928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia.
    Nair R; Salinas-Illarena A; Sponheimer M; Wullkopf I; Schreiber Y; Côrte-Real JV; Del Pozo Ben A; Marterer H; Thomas D; Geisslinger G; Cinatl J; Subklewe M; Baldauf HM
    Clin Exp Med; 2024 Jul; 24(1):155. PubMed ID: 39003408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1.
    Knecht KM; Buzovetsky O; Schneider C; Thomas D; Srikanth V; Kaderali L; Tofoleanu F; Reiss K; Ferreirós N; Geisslinger G; Batista VS; Ji X; Cinatl J; Keppler OT; Xiong Y
    Proc Natl Acad Sci U S A; 2018 Oct; 115(43):E10022-E10031. PubMed ID: 30305425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. With me or against me: Tumor suppressor and drug resistance activities of SAMHD1.
    Herold N; Rudd SG; Sanjiv K; Kutzner J; Myrberg IH; Paulin CBJ; Olsen TK; Helleday T; Henter JI; Schaller T
    Exp Hematol; 2017 Aug; 52():32-39. PubMed ID: 28502830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAMHD1 is a barrier to antimetabolite-based cancer therapies.
    Rudd SG; Schaller T; Herold N
    Mol Cell Oncol; 2017; 4(2):e1287554. PubMed ID: 28401188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia.
    Freisleben F; Behrmann L; Thaden V; Muschhammer J; Bokemeyer C; Fiedler W; Wellbrock J
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
    Abdelrazak Morsy MH; Lilienthal I; Lord M; Merrien M; Wasik AM; Sureda-Gómez M; Amador V; Johansson HJ; Lehtiö J; Garcia-Torre B; Martin-Subero JI; Tsesmetzis N; Tao S; Schinazi RF; Kim B; Sorteberg AL; Wickström M; Sheppard D; Rassidakis GZ; Taylor IA; Christensson B; Campo E; Herold N; Sander B
    Blood; 2024 May; 143(19):1953-1964. PubMed ID: 38237141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia.
    Marrero RJ; Cao X; Wu H; Elsayed AH; Klco JM; Ribeiro RC; Rubnitz JE; Ma X; Meshinchi S; Aplenc R; Kolb EA; Ries RE; Alonzo TA; Pounds SB; Lamba JK
    Blood Adv; 2023 Jun; 7(11):2538-2550. PubMed ID: 36689724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine.
    Rothenburger T; McLaughlin KM; Herold T; Schneider C; Oellerich T; Rothweiler F; Feber A; Fenton TR; Wass MN; Keppler OT; Michaelis M; Cinatl J
    Commun Biol; 2020 Jun; 3(1):324. PubMed ID: 32581304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interference with SAMHD1 Restores Late Gene Expression of Modified Vaccinia Virus Ankara in Human Dendritic Cells and Abrogates Type I Interferon Expression.
    Sliva K; Martin J; von Rhein C; Herrmann T; Weyrich A; Toda M; Schnierle BS
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.